Steve Sabus
Equibles does not estimate personal net worth.
About Steve Sabus
Syndax Pharmaceuticals Inc reported in an 8-K filed March 18, 2024 that Steve Sabus resigned as Chief Commercial Officer, effective March 15, 2024. Syndax Pharmaceuticals Inc reported in an 8-K filed December 5, 2022 that Steve Sabus was appointed Chief Commercial Officer, effective December 5, 2022. Syndax Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Syndax Pharmaceuticals Inc includes Michael A. Metzger (CEO and Board Member), Michael Metzger (CEO), Daphne Karydas (CFO) and 6 others.
“On March 15, 2024, Steve Sabus, the previous Chief Commercial Officer of the Company, notified the Company of his voluntary resignation from his position due to personal reasons.”
“On December 2, 2022, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that Steve Sabus will join the Company as Chief Commercial Officer, effective December 5, 2022.”
Affiliation history
-
Current
2022-12-05–present
-
2022-12-05–2024-03-15
Company network
Leadership on record at Syndax Pharmaceuticals Inc
- Michael A. Metzger CEO, Board Member
- Michael Metzger CEO
- Daphne Karydas CFO
- Keith A. Goldan CFO
- Keith Goldan CFO
- Luke J. Albrecht General Counsel
- Aleksandra Rizo, M.D., Ph.D. Board Member
- Martin H. Huber, M.D. Board Member
- Pierre Legault Board Member